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Follicular lymphoma (FL) shows co-expression of B-cell lymphoma 2 (BCL2) and
CD10, whereas downexpression of CD10 is occasionally experienced in gastroin-
testinal (GI) FL with unknown significance. Gastrointestinal FL is a rare variant of
FL, and its similarity with mucosa-associated lymphoid tissue lymphoma was
reported. We investigated the clinicopathological and genetic features of CD10
downexpressed (CD10down) GI-FL. The diagnosis of CD10down FL was carried out
with a combination of pathological and molecular analyses. The incidence of
CD10down GI-FL was shown in 35/172 (20.3%) cases, which was more frequent
than nodal FL (3.5%, P < 0.001). The difference was additionally significant
between GI-FL and nodal FL when the analysis was confined to primary GI-FL
(55.2% vs 3.5%, P < 0.001). Compared to CD10+ GI-FL, CD10down GI-FL signifi-
cantly involved the stomach or large intestine (P = 0.015), and additionally
showed the downexpression of BCL6 (P < 0.001). The follicular dendritic cell
meshwork often showed a duodenal pattern in the CD10down group (P = 0.12).
Furthermore, a lymphoepithelial lesion was observed in 5/12 (40%) gastric FL
cases, which indicated caution in the differentiation of mucosa-associated lym-
phoid tissue lymphoma. Molecular analyses were undertaken in seven cases of
CD10down GI-FL, and an identical clone was found between CD10down follicles and
CD10+BCL2+ neoplastic follicles. In the diagnosis of cases with CD10down BCL2+
follicles, careful examination with molecular studies should be carried out.
F ollicular lymphoma (FL) is the most common low-gradeB-cell lymphoma followed by mucosa-associated lymphoid
tissue (MALT) lymphoma.(1) Constitutive expression of the
anti-apoptotic protein B-cell lymphoma 2 (BCL2) by t(14;18)
(q32;q21)/IGH-BCL2 is the hallmark of this tumor. In addition,
it is an important immunohistochemical finding for the diagno-
sis of FL, in which BCL2 co-expresses with the germinal cen-
ter (GC) marker CD10. However, in FL of the gastrointestinal
(GI) tract, downexpression of CD10 is occasionally experi-
enced, which results in a differential diagnostic problem with
other low-grade lymphoma, although most of such cases usu-
ally accompany typical neoplastic follicles with the co-expres-
sion of CD10 and BCL2 (CD10+BCL2+) in the same lesion.
It was known that in nodal FL, downexpressed CD10
(CD10down) is associated with high grade disease and aggres-
sive clinical behavior.(2,3) In contrast, in the GI tract, most
cases of CD10down FL were low-grade tumors.(4,5) The fre-
quency and clinicopathological characteristics of CD10down FL
in the GI tract have not been well studied.
Approximately 15% of FL occurs in extranodal sites,(6) and
the GI tract is the most commonly affected site.(7,8) With the
recognition of this FL variant and the development of endo-
scopic technology, the characteristics of GI-FL have been
gradually revealed. Gastrointestinal FL is predominantly found
in the second part of the duodenum, and certain GI-FL spread
over the small intestine.(4,5,9) Although a case that showed a
transformation from duodenal FL to diffuse large B-cell lym-
phoma (DLBCL) was reported,(10) GI-FL is generally an indo-
lent disease, and certain cases showed spontaneous
regression.(11) Duodenal FL shares some characteristics with
MALT lymphoma, such as a lack of a follicular dendritic cell
(FDC) meshwork, the deviation of VH usage, a lack of activa-
tion-induced cytidine deaminase, and differentiation to memory
cells, which are different from nodal FL.(12) Furthermore, a
genetic similarity between duodenal FL and MALT lymphoma
was identified by comprehensive gene expression analysis.(13)
Considering these facts, downexpression of CD10 in GI-FL
may have a different level of significance from that in nodal FL.
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Therefore, in the present study, we investigated the clinical,
morphologic, and immunophenotypical features of CD10down
GI-FL and compared them with those of CD10+ GI-FL.
Materials and Methods
Patient selection. The cases retrieved from the consultation
files of the Department of Pathology, Okayama University
Graduate School of Medicine, Dentistry, and Pharmaceutical
Sciences (Okayama, Japan) included 172 cases of GI-FL
(1993–2012), 144 cases of nodal FL (2012–2013), and 1024
cases of MALT lymphoma in the GI tract (1989–2013). Cases
of FL in situ, grade 3 FL, and FL with a diffuse area or
DLBCL in other sites were excluded from the present study.
CD10down FL was defined by one of the following findings
(Fig. 1): (i) the presence of the co-expression of CD10/BCL6
and BCL2 in parts of the typical neoplastic follicles, which are
composed of small- to medium-sized cells along with a few
large-sized cells (grade 1–2); or (ii) the translocation of IGH/
BCL2 in CD10down tumor follicles using FISH; (iii) an identi-
cal clone verified between CD10down follicles and typical
CD10+BCL2+ neoplastic follicles by PCR; or (iv) the presence
of CD10+BCL2+ neoplastic follicles in different samples taken
from the same lesion.
Complete clinical information was obtained from 58 of 172
cases of GI-FL. The International Workshop classification
(Lugano classification)(14) was used for the clinical staging of
GI-FL. Twenty-nine of 58 cases with stage I and II1 were
recognized as a primary GI-FL.(5) The site of involvement
was based on biopsy or operation specimens. The Follicular
Lymphoma International Prognostic Index was used for the
evaluation of patient status.(15) The study protocol was
approved by the Institutional Review Board of Okayama
University (Okayama, Japan). All study procedures were
Fig. 1. Schema of criteria for CD10 downexpressed (CD10down) follicular lymphoma. (a) Presence of the coexpression of CD10/BCL6 (1, orange
dot) and BCL2 (2, green dot) in parts of the typical neoplastic follicles (blue circle) using immunohistochemistry. (b) Translocation of IGH/BCL2
(yellow dot) in CD10down tumor follicles (white circle) using FISH. (c) Identical clone between CD10down follicles (1) and typical neoplastic follicles
with the coexpression of CD10 and BCL2 (2) using PCR. (d) Presence of typical neoplastic follicles with coexpression of CD10 and BCL2 (1) and
CD10down follicle (2) in different samples taken from the same lesion.
Table 1. Antibodies used in this study
Antibody Source Clone Dilution
CD20 Novocastra, Newcastle Upon Tyne, UK L26 1:200
CD3 Novocastra, Newcastle Upon Tyne, UK LN10 1:50
CD10 Novocastra, Newcastle Upon Tyne, UK 56C6 1:50
BCL2 Novocastra, Newcastle Upon Tyne, UK 3.1 1:200
BCL6 Santa Cruz Biotechnology, Santa Cruz, CA, USA D-8 1:100
CD21 Dako, Glostrup, Denmark 1F8 1:20
Cyclin D1 Nichirei, Tokyo, Japan SP4 Ready to use
CAM5.2 Becton Dickinson, Franklin Lakes, IL, USA CAM5.2 Ready to use
Table 2. Comparison of CD10 expression between nodal and
gastrointestinal (GI) follicular lymphoma
CD10+ CD10 downexpressed P-value
Nodal lesion (primary nodal)
(n=144)
139 5
GI lesion (n=172) 137 35 <0.001
Primary nodal (n=144) 139 5
Primary GI (n=29) 13 16 <0.001
Bold values indicate significance. Downexpressed, ≤50% positive cells in
neoplastic follicles; positive, >50% positive cells in neoplastic follicles.
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carried out in accordance with guidelines of the Declaration
of Helsinki.
Histology and immunohistochemistry. Histological and
immunophenotypical features were studied on 10% formalin-
fixed paraffin-embedded tissue sections (FFPET). Immunohis-
tochemistry was carried out using an automated Bond-Max
stainer (Leica Biosystems, Nussloch, Germany) according to
the manufacturer’s instructions. The primary antibodies used in
the present study are summarized in Table 1. The expression
of CD10 and BCL6 were scored as positive (>50% positive
cells in neoplastic follicles) or downexpressed (≤50% positive
cells in neoplastic follicles).
In the present study, samples that included no obvious fol-
licles in sections were categorized as positive for CD10 and
BCL6. The FDC pattern was classified as nodal (>30%
positive FDC cells), intermediate (5–30% positive FDC
cells), and duodenal (<5% positive FDC cells and FDC
located at the periphery tumor follicles), as previously
(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
Fig. 2. Pathological features of CD10 downexpressed gastrointestinal follicular lymphoma (FL). (a) Neoplastic follicles are present in the lamina
propria mucosa (HE, 9200). (b) Tumor cells were composed of a monotonous population of small- to medium-sized and a few large-sized cells
(HE, 9400). (c) CD20 was positive, and (d) CD3 was negative in the neoplastic follicle. (e) CD10 was downexpressed in the neoplastic follicle
(9400). (f) BCL2 was positive (9400). (g) BCL6 was downexpressed (9400). (h) A few Ki-67+ cells were seen. (i) CD21+ follicular dendritic cells pre-
sent at the periphery of the neoplastic follicle (duodenal pattern).
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described.(12) Three cases that showed both nodal and
duodenal patterns were excluded from the comparison of
FDC patterns, and three cases that showed both duodenal
and intermediate patterns were classified as the duodenal
pattern.
Polymerase chain reaction (IGH). DNA was extracted from
FFPET, and PCR reactions were undertaken according to the
BIOMED-2 Concerted Action protocol.(16) The IGH frame-
work region 3 (FR3) primer was used as previously
described.(12,16,17)
Fluorescence in situ hybridization for IGH/BCL2. To detect
IGH/BCL2 translocation for CD10 negative follicles, instant
quality FISH was carried out using Agilent FISH General Pur-
pose Reagents (Agilent Technologies, Santa Clara, CA, USA)
following the manufacturer’s instructions. Fluorescence in situ
hybridization was carried out on FFPET, and the spectrum
red-labeled BCL2 probe (18q21.33 BCL2 DF 994 kb) and the
spectrum green-labeled IGH probe (14q32.33 IGH DF 1519 kb
P5) were used. Each case was interpreted as positive for IGH/
BCL2 translocation if a fusion signal was observed in more
than 7% of nuclei, according to a previous report.(18)
Statistical analyses. Student’s t-test or the v2-test was used.
A P-value <0.05 was considered statistically significant. All
statistical analyses were undertaken using the SPSS software
package (version 14.0; SPSS, Chicago, IL, USA).
Results
Clinical features. The morphology and immunohistochemistry
of CD10down GI-FL are shown in Fig. 2. The frequency and
clinicopathological features of CD10down GI-FL and nodal FL
are summarized in Tables 2 and 3.
A total of 172 cases of FL in the GI tract included 82 male
and 90 female patients with a median age of 60.5 years (range,
37–85 years), and 144 cases of FL in the lymph node included
60 male and 84 female patients with a median age of
63.5 years (range, 32–84 years). Among each of the FL cases,
35 cases in the GI tract (20.3%, 18 men and 17 women) and
five cases (3.5%, 5 women) in the lymph node were classified
as within the CD10down group. CD10 downexpression was con-
sequently significantly more frequent in GI-FL than in nodal
FL (3.5%, P < 0.001; Table 2). In addition, when we confined
the analysis to primary GI-FL, the difference was additionally
significant between GI-FL and nodal FL (55.2% vs 3.5%,
P < 0.001; Table 2).
Table 3. Comparison between CD10-positive and CD10 down-
expressed FL
CD10
positive
CD10
downexpressed P value
n=137 n=35
Site of involvement of
GI tract (all cases, n=172)
Small intestine only 128 28
Stomach or large intestine
with/without small intestine
9 7 0.015
Site of involvement of GI
(primary GI-FL cases, n=29)
Small intestine only 13 13
Stomach or large intestine
with/without small intestine
0 3 0.099
Sex
Male 16 15
Female 15 12 0.76
Age: median(range) 59 (40–85) 63 (38–78) 0.75
Ann-Arbor staging
1,2 23 18
3,4 8 9 0.53
Lugano classification
I–II1 13 16
II2–IV 17 11 0.23
FLIPI
Low 18 14
Intermediate 7 7
High 4 5 0.80
Anemia*
Present 1 1
Absent 29 24 0.90
LDH
Normal 22 20
Elevated 8 5 0.56
sIL-2R
Normal 20 12
Elevated 8 6 0.73
WBC (/ll)
<9000 30 25
9000< 0 1 0.28
Thrombocytopenia**
Present 7 4
Absent 23 21 0.50
Hypoalbuminemia***
Present 2 2
Absent 25 17 0.71
Hypocalcemia****
Present 4 2
Absent 14 21 0.22
Primary therapy
Watchful wait 17 17
R 3 2
R-CHOP 4 2
CHOP and CHOP-like 4 2
operation or endoscopic
resection
2 2
Other 1 1
Unknown 1
Follow-up time: median
(range) (month)
68 (7–157) 70 (1–201) 0.42
Table 3 (Continued)
CD10
positive
CD10
downexpressed P value
n=137 n=35
BCL6
Positive 12 4
Negative 5 22 <0.001
FDC pattern
Duodenal 9 19
Nodal 6 4 0.12
*Anemia; serum hemoglobin level <12 g/dL (male), <10 g/dL (female)
**Thrombocytopenia, serum platelet level <150,000/lL ***Hypoalbu-
minemia, serum albumin level <3.9 g/dL ****Hypocalcemia, serum cal-
cium level <8.6 mg/dL
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The clinical information of GI-FL was obtained in 58 cases
(31 CD10+ GI-FL and 27 CD10down GI-FL). The median fol-
low-up time of the CD10+ GI-FL group was 68 months, and
that of the CD10down GI-FL group was 70 months. More than
50% of cases were followed up without any treatment (watch
and wait), and no patient died of the primary disease.
CD10down GI-FL significantly involved the stomach and/or
large intestine (P = 0.015), and all cases involved the small
intestine. When confined to primary GI-FL, CD10down GI-FL
tended to involve the stomach and/or the large intestine
although it was not significant (P = 0.099; Table 3). There
was no significant difference in other clinical characteristics.
In the present study, the entire gastrointestinal tract was
examined using double balloon endoscopy and/or capsule
endoscopy in 13 cases, and all involved the duodenum. Two
cases (one CD10+ case, one CD10down case) were localized in
the duodenum, and 11 cases (five CD10+ cases, six CD10down
cases) involved the duodenum and other parts of the small
intestine. There was no significant difference between these
two groups in CD10 expression (P = 0.91) and other clinico-
pathological characteristics.
Pathological features. There was no difference in the mor-
phology of CD10down GI-FL and CD10+ GI-FL, and both
showed neoplastic follicles composed of monotonous tumor
cells of a small to medium size and a few large-sized cells
without tingible body macrophages.
It was found that BCL6 was significantly downexpressed in
CD10down GI-FL (P < 0.001). Duodenal pattern of FDC was
often observed in CD10down GI-FL, although there was no sig-
nificant difference (P = 0.12; Table 3). The pathological fea-
tures of the 35 cases of CD10down GI-FL are shown in
Table 4. The average proportion of CD10+ and BCL6+ tumor
cells in the follicle were 12.6% (range, 0–50%) and 28.5%
(range, 0–100%), respectively.
Lymphoepithelial lesions (LEL) in gastric lesions were
observed in 5/12 (41.6%) cases (Fig. 3). The macroscopic
Table 4. Immunohistochemical and immunogenotypical results in 35 cases of CD10 downexpressed follicular lymphoma
Patient
no.
Age, years Sex
Site of
involvement†
Proportion of
CD10+ cells,‡ %
Proportion of
BCL6+ cells,‡ %
PCR* FISH** CD10+ lesion*** CD21
1 73 M SI 0 ND 1 ND 1 Duodenal
2 73 M SI 10 100 1 ND 1 Nodal
3 67 M SI 20 20 1 ND 2 Mismatch
4 66 F SI 50 <10 1 ND 1 ND
5 54 M St, SI, LI 20 10 1 ND 1 Duodenal
6 61 M SI 0 0 1 ND 1 Duodenal
7 51 M SI 0 20 1 ND 1 Duodenal
8 54 M St, SI <10 30 2 + 1 Mismatch
9 66 F SI 20 20 2 + 1 ND
10 37 F SI <10 0 ND + 1 ND
11 55 M SI 0 100 2 ND 1 Duodenal
12 69 F SI 50 <10 2 ND 1 Duodenal
13 63 M SI 0 0 2 + 2 Duodenal
14 52 M SI 0 100 2 ND 1 Duodenal
15 54 M SI 0 15 2 ND 1 Nodal
16 69 F SI 30 0 ND ND 1 Duodenal
17 61 F SI 0 100 ND ND 1 Duodenal
18 73 F SI 40 10 ND ND 0 Duodenal
19 56 M SI 0 30 ND ND 1 ND
20 76 F SI 30 30 ND ND 1 Mismatch
21 68 M SI 20 ND ND ND 1 ND
22 55 F SI 30 ND ND ND 1 Duodenal
23 75 F SI 20 ND ND ND 1 ND
24 48 M St, SI 0 15 ND ND 1 ND
25 65 M SI 0 ND ND ND 1 Nodal
26 57 F SI 10 ND ND ND 1 ND
27 64 F SI 0 20 ND ND 1 Duodenal
28 78 F SI 30 ND ND ND 1 Duodenal
29 58 M St, SI 0 20 ND ND 1 Nodal
30 38 F St, SI, LI 0 30 ND + 1 Duodenal
31 46 F SI 0 10 ND ND 1 Duodenal
32 45 M St, SI, LI 20 ND ND ND 1 ND
33 70 F SI 20 0 ND ND 1 Duodenal
34 62 M St, SI 0 50 ND ND 2 Duodenal
35 49 F SI 10 ND ND ND 1 Duodenal
LI, large intestine; ND, not done; SI, small intestine; St, stomach. †Italic text indicates sites where CD10 downexpressed follicles were seen. ‡<10
indicates <10% CD10+ or BCL6+ tumor cells. *1, identical clone between CD10 downexpressed follicles and typical CD10 and BCL2 positive neo-
plastic follicles; 2, negative in both CD10 downexpressed follicles and typical CD10 and BCL2 positive neoplastic follicles. **+, positive for a IgH/
BCL2 translocation (a fusion signal was observed in more than 7% of nuclei). ***0, the case without CD10 positive neoplastic follicles in the gas-
trointestinal (GI) tract; 1, the case with CD10 positive neoplastic follicles in same lesion; 2, the case with CD10 positive neoplastic follicles in
another GI lesion.
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findings of these five cases were as follows: two cases pre-
sented with a submucosal tumor-like lesion, one with multiple
nodules, one with multiple nodules on a flat elevated lesion,
and one was unknown. Three cases were in the CD10+ group,
and the remaining two cases were in the CD10down group.
Molecular features. The results of PCR and FISH in 35 cases
of CD10down GI-FL are shown in Table 4. Polymerase chain
reaction analysis was undertaken for 14 cases. Seven cases
were successfully amplified, and in all cases, an identical clone
was found between CD10down follicles and CD10+BCL2+ neo-
plastic follicles (Fig. 4a,b). Five cases were examined for fur-
ther FISH analysis (three duodenal lesions and two ileal
lesions), and all five cases of CD10down GI-FL showed IGH/
BCL2 translocation (Fig. 4c). The diagnostic algorithm in
CD10down GI-FL is shown in Fig. 5.
Discussion
In the present study, we found that CD10 downexpression was
frequently observed along with an additional distinct feature of
GI-FL. CD10down GI-FL frequently involved the stomach or
large intestine, and showed the simultaneous downexpression
of BCL6. Furthermore, gastric FL occasionally contained LEL
in parts of the lesions.
For the diagnosis of CD10down FL, a careful differentiation
of the follicular colonization of MALT lymphoma and normal
primary follicles is always required because both have identi-
cal immunohistochemical features (CD10/BCL6 and
BCL2+). Follicular colonization is the phenomenon in which
MALT lymphoma invades to reactive GC and closely resem-
bles FL.(8,19,20) In the present study, we carefully excluded
MALT lymphoma showing this phenomenon, and diagnosed
CD10down FL by one of the following findings: (i) the presence
of the co-expression of CD10/BCL6 and BCL2 in parts of the
typical neoplastic follicles that are composed of small- to med-
ium-sized and a few large-sized cells (grade 1–2); (ii) the
translocation of IGH/BCL2 in CD10down tumor follicles by
FISH; (iii) an identical clone between CD10down follicles and
CD10+BCL2+ neoplastic follicles using PCR; or (iv) the pres-
ence of CD10+BCL2+ neoplastic follicles in different samples
taken from the same lesion. In the diagnosis of these cases, as
shown in the algorithm for the diagnosis of CD10down GI-FL,
it is important to carefully search for the evidence of FL. Fol-
lowing the above criteria, the addition of BCL6 staining, the
re-biopsy of several areas, and the examination of the translo-
cation of IGH/BCL2 using FISH, and an identical clone veri-
fied between CD10down follicles and typical CD10+BCL2+
neoplastic follicles using PCR is required.
Similarity between GI-FL and MALT lymphoma was
described in several previous studies. Both were frequently
present within localized diseases, resulted in indolent clinical
behavior,(21–23) and shared gene expression profiles.(12,13)
(a) (b) (c)
(d) (e) (f)
Fig. 3. Representative case of gastric follicular lymphoma with lymphoepithelial lesion (LEL). (a) Diffuse proliferation of small- to medium-sized
cells were seen in the proper mucosa (HE, 9100). (b–d) LEL with neoplastic B cells. (b) HE, 9400. (c) CAM 5.2 staining, 9400. (d) CD20 staining,
9400. (e) CD10 was positive (arrows) but downexpressed around the LEL area. (f) BCL2 was strongly positive in both CD10+ (arrows) and CD10
downexpressed areas.
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Interestingly, it has been reported that, similar to MALT lym-
phoma, certain GI-FL showed partial regression after antibiotic
treatment.(9,24,25) The frequent downexpression of GC markers
(CD10 and BCL6) in GI-FL of the present study was consis-
tent with these previous data.
In the present study, LEL was shown in 40% of FL with gas-
tric lesion. It is considered that LEL is a characteristic finding of
MALT lymphoma in which lymphoma cells have invaded and
destroyed the epithelium.(8) It was of interest that a few cases of
GI-FL additionally showed LEL. It should be kept in mind that
LEL itself was not a MALT-specific phenomenon.
Follicular lymphoma with marginal zone differentiation is
known to show morphological features, such as marginal zone
lymphoma (MZL) in parts of FL, and have both CD10+BCL2+
neoplastic follicles of FL and the morphology of MZL, with
monocytoid or plasmacytoid B cells in the interfollicular area.
CD10 down-expressed follicle.
133nt
133nt
CD10 posive follicle.
(a)
(b)
(c)
Fig. 4. (a,b) Polymerase chain reaction for immunoglobulin heavy chain rearrangements in with gastrointestinal follicular lymphoma. Identical
clone (133 nt) was detected between CD10 downexpressed (a) and CD10+BCL2+ follicles (b) in the same patient. (c) FISH for IGH/BCL2 transloca-
tion in CD10 downexpressed tumor follicle. Fusion signal for IGH/BCL2 (yellow signal; arrow) was seen.
Fig. 5. Algorithm of diagnosis in CD10 downexpressed gastrointestinal follicular lymphoma (GI-FL). IHC, immunohistochemistry.
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It is considered that this is not composite lymphoma, but that
the two components are clonally related.(26,27) Follicular lym-
phoma with LEL could be considered as FL with marginal
zone differentiation because parts of them have a similar mor-
phology to MZL. These cases might be misdiagnosed as
MALT lymphoma if a CD10+ area is not obtained in the small
biopsy specimen. Therefore, FL with marginal zone differenti-
ation is one of the important differential diagnoses of MALT
lymphoma, particularly in patients with a history of FL.
Macroscopic findings of typical FL in the small intestine
were described as multiple white nodules,(4,9) and FL in the
stomach could show various appearances. In MALT lymphoma
in the stomach, various appearances were observed such as
flat, elevating, and ulcerative lesions, however, multiple nod-
ules were extremely rare.(23,28,29) In the present study, two of
four cases of FL with LEL did not show characteristic macro-
scopic appearances of MALT lymphoma. Considering these
facts, when we diagnose MALT lymphoma with LEL showing
an endoscopically atypical appearance of MALT lymphoma,
careful examination should be required to avoid misdiagnosis.
We have previously reported a case that was initially diag-
nosed as MALT lymphoma in the ileum and FL in the jejunum
but was subsequently diagnosed as FL with marginal differen-
tiation.(30) Although only a diffuse proliferation of medium-
sized CD10BCL2+ cells was observed in the ileal lesion, it
was shown that both lesions had IGH/BCL2 using FISH and
an identical band was found using Southern blot. In the present
study we categorized the CD10down group as those with obvi-
ous follicles with ≤50% CD10+ cells. However, there would be
FL cases with CD10 cells with only diffuse proliferation like
this case report. Considering these facts, the number of
CD10down FL cases could be more than what we analyzed.
Table 5 shows the site of involvement of CD10down GI-FL,
CD10+ GI-FL, and MALT lymphoma. Among the 1024
MALT lymphoma cases, 815 cases (79.6%) involved the stom-
ach, 176 cases (17.2%) involved the large intestine, and 32
cases (3.1%) involved the small intestine. In contrast to MALT
lymphoma, the majority of CD10+ FL cases (97.1%) involved
the small intestine, and the involvement of the stomach or
large intestine was extremely rare. In CD10down GI-FL,
although all cases were presented with small intestinal lesion,
they additionally tended to involve the stomach (20%) or large
intestine (5.7%). As described above, this phenomenon may be
one of the characteristics in CD10down GI-FL. Because most of
the cases were diagnosed by biopsy in the present study, the
distribution (diffuse or focal) of CD10down neoplastic follicles
is difficult to describe, as this would require an examination of
the distribution of CD10down neoplastic follicles by several
biopsies over a wide area in the same organ using immunohis-
tochemistry and molecular study. Therefore, this aspect is a
subject for future research.
Further discussion is required regarding the cut-off value of
CD10 in GI-FL. In one previous report, the cut-off value of
CD10 was 30%(12); however, the cut-off values of CD10 in
several reports were not explicitly set.(4,31) Furthermore, in a
previous report regarding CD10 expression in primary intesti-
nal DLBCL, CD10 staining was scored simply as positive or
negative without setting the cut-off value.(32) It is suggested
that there is currently no consensus on the cut-off value of
CD10 in GI lymphomas. We reclassified FL by setting the
cut-off value of CD10 downexpressed at 30% and repeated
the comparison between the clinicopathological characteristics
of CD10+ and CD10down FL. As a result, a similar tendency
was observed: CD10 downexpression was significantly more
frequent in GI-FL than in nodal FL (P < 0.001). Even if con-
fined to primary GI-FL, the difference was also significant
between GI-FL and nodal FL (P < 0.001). CD10down GI-FL
significantly involved the stomach and/or large intestine
(P = 0.007), and BCL6 was significantly downexpressed in
CD10down GI-FL (P = 0.004). We believe that this occurred
because the proportion of CD10+ cell was <30% in most
CD10down cases, as shown in Table 4. In addition, unlike
biopsy specimens of lymph nodes, biopsy specimens of GI
lymphomas are very small and easily crushed. Based on these
facts, we set the cut-off value of CD10 downexpressed to
50% to prevent a complicated diagnosis and to improve repro-
ducibility.
In conclusion, CD10 downexpression was more frequent in
GI-FL than in nodal FL and significantly involved the stomach
or large intestine. Furthermore, gastric FL occasionally had
LEL in part of the lesion. In the diagnosis of cases with
CD10down BCL2+ follicles, molecular analysis should be
undertaken. Further prospective studies are warranted to clarify
the pathophysiology of GI-FL.
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